Montag & Associates’s Edgewise Therapeutics EWTX Stock Holding History

Montag & Associates’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-16	Closed	-$260	–	1028
2025 Q3	$260	Buy	+16	New	+$227	﹤0.01%	1111

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Montag & Associates's EWTX Position: Q4 2025 in Review

Montag & Associates sold out of Edgewise Therapeutics (EWTX) in Q4 2025, closing a stake of 16 shares — an estimated $260 sold.

Montag & Associates first reported a position in EWTX in Q3 2025 and held it in 1 quarter. The position peaked at $260 in Q3 2025. 199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

Montag & Associates reported no remaining Edgewise Therapeutics position as of Q4 2025 after selling out during the quarter.
Montag & Associates sold 16 Edgewise Therapeutics shares in Q4 2025, an estimated $260.
Montag & Associates first reported a position in Edgewise Therapeutics in Q3 2025 and held it in 1 quarter.
Montag & Associates's Edgewise Therapeutics position peaked at $260 in Q3 2025.
199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.